<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Cohen, David J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Reappraisal of the Current Guidelines with Respect to Preloading before PCI May Be Warranted</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">Both the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery myocardial revascularization guidelines [Wijns W et al. Eur Heart J 2010] and American College of Cardiology Foundation, American Heart Association, and Society for Cardiovascular Angiography and Interventions percutaneous coronary intervention (PCI) guidelines [Levine GN et al. J Am Coll Cardiol 2011] recommend (with a Class I recommendation) the use of a loading dose of a P2Y12 receptor inhibitor before PCI with stenting. This article discusses alternatives to the Class I recommendation.</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>